Skip to Content
AP National Business

Ultragenyx: Q4 Earnings Snapshot

By
Published 2:52 PM

NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $151.8 million in its fourth quarter.

The Novato, California-based company said it had a loss of $2.16 per share.

The results missed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $2.03 per share.

The biotechnology company posted revenue of $103.3 million in the period, surpassing Street forecasts. Nine analysts surveyed by Zacks expected $103.1 million.

For the year, the company reported a loss of $707.4 million, or $10.12 per share. Revenue was reported as $363.3 million.

Ultragenyx expects full-year revenue in the range of $425 million to $450 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE

Article Topic Follows: AP National Business

Jump to comments ↓

Associated Press

BE PART OF THE CONVERSATION

KION 46 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content